

FOR IMMEDIATE RELEASE

HC Surgical Acquires 51% of Chirurgia Pte. Ltd.

Highlights

- **Dr. Lee Lip Seng, an experienced hepatopancreatobiliary surgeon, with more than 20 years' experience, joins HC Surgical Specialists Limited.**
- **Dr. Lee will manage Chirurgia Pte. Ltd. for a minimum of 10 years.**
- **The addition of Dr. Lee to the Group's stable of experienced specialists will strengthen the Group's capabilities.**

Singapore, 6 April 2026 – Catalyst-listed HC Surgical Specialists Limited (SGX:1B1) (“HCSS”, or the “Company” and collectively with its subsidiaries, the “Group”) is pleased to announce that it has today entered into a sale and purchase agreement with Dr. Lee Lip Seng (“**Dr. Lee**”) for the acquisition of 51% of the total issued and paid-up share capital of Chirurgia Pte. Ltd. (“**Chirurgia**”) from Dr. Lee, for a total purchase consideration of S\$1,228,000 (the “**Purchase Consideration**”) (the “**Proposed Acquisition**”).

Chirurgia was incorporated on 31 July 2022 in the Republic of Singapore and operates out of a clinic called “LS Lee Surgery” in Mount Elizabeth Novena Hospital. The principal activity of Chirurgia is the provision of minimally invasive surgery and treatment of gallbladder diseases, which offers synergy with the Group’s general surgery and endoscopy services. Dr. Lee is an experienced hepatopancreatobiliary (“**HPB**”) surgeon, specialising in minimally invasive surgery (laparoscopic and robotic surgery) for the treatment of liver, pancreatic and biliary, gallbladder diseases and cancers. He obtained his medical degree from Royal College of Surgeons in Ireland in 2005, completed his Surgery Specialist Training at both Changi General Hospital and Singapore General Hospital in 2013, and his Clinical Fellowship Training in Minimally Invasive



Incorporated in the Republic of Singapore
Registration No. 201533429G

Surgery (Laparoscopic and Robotic Surgery) in Korea in 2015. Prior to leaving for private practice, he served as the Director of the HPB Service at Changi General Hospital.

Chief Executive Officer of HCSS, Dr. Heah Sieu Min commented, ***“We are delighted to welcome Dr. Lee, our first HPB surgeon to the Group. His onboarding is in line with our business expansion strategy to broaden the spectrum of our medical services, on top of the synergy between his specialty with the Group’s general surgery and endoscopy service. Dr. Lee’s many years of experience will be a valuable asset to the Group.”***

Dr. Lee commented, ***“I am honoured to be part of HCSS. I look forward to bringing my HPB surgical expertise to deliver patient-centric care and achieve quality clinical outcomes for our patients.”***

The total Purchase Consideration will be satisfied by internal resources. The Company intends to enter into a separate sale and purchase agreement to buy the remaining 49% of the total issued and paid-up share capital in Chirurgia at a later stage.

– End –

About HC Surgical Specialists Limited

HC Surgical Specialists Limited (“**HCSS**”) was incorporated on 1 September 2015 in Singapore and listed on the Catalist of the Singapore Exchange Securities Trading Limited on 3 November 2016. HCSS, its subsidiaries and associated company are a medical services group primarily engaged in the provision of endoscopic procedures, including gastroscopies and colonoscopies and general surgery services with a focus on colorectal procedures across a network of 18 clinics located throughout Singapore. For more information, please visit HCSS’ website at www.hcsurgicalspecialists.com.



Incorporated in the Republic of Singapore
Registration No. 201533429G

Issued By : HC Surgical Specialists Limited

Investor Relations Contact : contact@hcsurgicalspecialists.com

This press release has been reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #04-02 Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.